{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:04:10Z","timestamp":1794557050768,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00198-011-1847-z","type":"journal-article","created":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T16:19:03Z","timestamp":1322497143000},"page":"1115-1122","source":"Crossref","is-referenced-by-count":89,"title":["Maintenance of antifracture efficacy over 10\u00a0years with strontium ranelate in postmenopausal osteoporosis"],"prefix":"10.1007","volume":"23","author":[{"given":"J-Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Diaz-Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Badurski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,29]]},"reference":[{"key":"1847_CR1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstrom","year":"2004","unstructured":"Mellstrom DD, Sorensen OH, Goemaere S et al (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462\u20138","journal-title":"Calcif Tissue Int"},{"key":"1847_CR2","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u201338","journal-title":"JAMA"},{"key":"1847_CR3","doi-asserted-by":"crossref","unstructured":"Black DM, Reid I, Cauley J et al. (2010) The effect of 3 versus 6\u00a0years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Abstract 1070. J Bone Miner Res 25 (suppl 1):","DOI":"10.1016\/j.bone.2011.03.127"},{"key":"1847_CR4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751\u201361","journal-title":"J Natl Cancer Inst"},{"key":"1847_CR5","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","volume":"20","author":"ES Siris","year":"2005","unstructured":"Siris ES, Harris ST, Eastell R et al (2005) Skeletal effects of raloxifene after 8\u00a0years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20:1514\u201324","journal-title":"J Bone Miner Res"},{"issue":"suppl 1","key":"1847_CR6","first-page":"S107","volume":"22","author":"S Papapoulos","year":"2011","unstructured":"Papapoulos S, Man Z, Mellstrom D et al (2011) Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension. OC24. Osteoporos Int 22(suppl 1):S107","journal-title":"Osteoporos Int"},{"key":"1847_CR7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M et al (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394\u2013402","journal-title":"J Clin Endocrinol Metab"},{"key":"1847_CR8","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.bone.2007.02.003","volume":"40","author":"PJ Marie","year":"2007","unstructured":"Marie PJ (2007) Strontium ranelate: new insights into its dual mode of action. Bone 40:S5\u2013S8","journal-title":"Bone"},{"key":"1847_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u201368","journal-title":"N Engl J Med"},{"key":"1847_CR10","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u201322","journal-title":"J Clin Endocrinol Metab"},{"key":"1847_CR11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","volume":"21","author":"C Roux","year":"2006","unstructured":"Roux C, Reginster J-Y, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536\u201342","journal-title":"J Bone Miner Res"},{"key":"1847_CR12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.23461","volume":"58","author":"JY Reginster","year":"2008","unstructured":"Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687\u201395","journal-title":"Arthritis Rheum"},{"key":"1847_CR13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bone.2009.08.004","volume":"45","author":"JY Reginster","year":"2009","unstructured":"Reginster JY, Bruyere O, Sawicki A et al (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8\u00a0years. Bone 45:1059\u201364","journal-title":"Bone"},{"key":"1847_CR14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, Van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u201348","journal-title":"J Bone Miner Res"},{"key":"1847_CR15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1385\/JCD:2:1:37","volume":"2","author":"DO Slosman","year":"1999","unstructured":"Slosman DO, Provvedini DM, Meunier PJ et al (1999) The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. Consequences and limits J Clin Densitom 2:37\u201344","journal-title":"Consequences and limits. J Clin Densitom"},{"key":"1847_CR16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u201397","journal-title":"Osteoporos Int"},{"key":"1847_CR17","unstructured":"WHO Collaborating Centre for Metabolic Bone Diseases (2008) FRAX WHO fracture risk assessment tool. Available at: http:\/\/www.shef.ac.uk\/FRAX\/ . Accessed 27 April 2011"},{"key":"1847_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","volume":"74","author":"K Briot","year":"2007","unstructured":"Briot K, Tremollieres F, Thomas T et al (2007) How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 74:24\u201331","journal-title":"Joint Bone Spine"},{"key":"1847_CR19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u201399","journal-title":"N Engl J Med"},{"key":"1847_CR20","doi-asserted-by":"crossref","unstructured":"Kanis JA, Johansson H, Oden A et al. (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int In press","DOI":"10.1007\/s00198-011-1683-1"},{"key":"1847_CR21","unstructured":"McCloskey E, Johansson H, Oden A et al. (2011) Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Abstract OC15. Osteoporos Int 22 (suppl 1):S103"},{"key":"1847_CR22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV McCloskey","year":"2009","unstructured":"McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811\u20137","journal-title":"Osteoporos Int"},{"key":"1847_CR23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u201382","journal-title":"JAMA"},{"key":"1847_CR24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/sim.3870","volume":"29","author":"E Vittinghoff","year":"2010","unstructured":"Vittinghoff E, McCulloch CE, Woo C et al (2010) Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med 29:1127\u201336","journal-title":"Stat Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00198-011-1847-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T02:54:00Z","timestamp":1639796040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1847-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,29]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1847-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,29]]}}}